JLS Fund

Investments at the Intersection of Neuroscience, Psychedelics & Technology

[JLS Fund @FundJls]

@RepMichaelRulli You might enjoy this, Congressman. An interview with Stanford neuroscientist Kenneth Shinozuka, who discussed his research into ibogaine as a potential treatment for traumatic brain injury, PTSD, depression, and addiction. https://t.co/Pr8tP8FFU6

[Experience Ibogaine Treatment Center @experienceiboga]

Ibogaine interacts with serotonin, dopamine, and opioid pathways in the brain. Many people report reduced withdrawal symptoms and shifts in addictive thought patterns after treatment.

Learn more: https://t.co/FU4WR0PEZh

#ExperienceIbogaine #Ibogaine #RecoverySupport

[JLS Fund @FundJls]

What an amazing interview with Stanford neuroscientist @kfshinozuka , who discussed his research into #ibogaine as a potential treatment for traumatic brain injury, #PTSD, #depression, and #addiction.  Absolutely fascinating! https://t.co/cuOEGFmXFl

[JLS Fund @FundJls]

https://t.co/PZh2yMJgJd #alzheimers #psychedelics #psilocybin

[JLS Fund @FundJls]

INmune Bio Reports Positive MRI Findings in Phase 2 Alzheimer's Study: https://t.co/RTcYlrlq0D $INMB @INmuneBio

[JLS Fund @FundJls]

https://t.co/tNTy8Wfxi4 #parkinsons @MichaelJFoxOrg

[JLS Fund @FundJls]

https://t.co/24rs9b8GHF #psilocybin @Optimi_Health

[JLS Fund @FundJls]

https://t.co/6u95RBhlaw

[JLS Fund @FundJls]

https://t.co/PndN6J6cUL @PharmAlaBiotech @jupiterneuro #psychedelics

[JLS Fund @FundJls]

Will the combination of AI and synthetic biology allow humans to design, modify, and create entirely new forms of life by rewriting genetic code itself?

Check out this fascinating conversation with @AdrianWoolfson and see what you think: https://t.co/zHZ8DrObaT

[JLS Fund @FundJls]

https://t.co/2kZOgw67Xg #parkinsons @BioVie_Pharma

[JLS Fund @FundJls]

@C_Angermayer @enhanced_games So excited for this!

[JLS Fund @FundJls]

https://t.co/y8aELya5Vm #parkinsons @cerevance

[JLS Fund @FundJls]

https://t.co/PAWRxfT6ID @CellularIntelHQ #parkinsons

[JLS Fund @FundJls]

https://t.co/hKRr5vQgMY #psychedelics #cocaine

[JLS Fund @FundJls]

https://t.co/sXEyzKU6fm #depression @NRxPharma

[Helus Pharma @Helus_Pharma]

"Health innovation must not only extend life, but improve quality of life."

Helus Pharma Interim CEO Eric So (@EricSo168168) highlighted the need for better outcomes for people living with #MajorDepressiveDisorder, including improved tolerability beyond first-line SSRI/SNRI therapies, during the “New Wave of Health Innovation” panel at the 29th annual @MilkenInstitute Global Conference.

[JLS Fund @FundJls]

New Study Links Psilocybin to Structural Changes in the Brain: https://t.co/ZUOc1C6Vnc #psychedelics #psilocybin

[JLS Fund @FundJls]

https://t.co/yudFCpAO6Z #alzheimers @mmimicro_inc

[MMI - Medical Microinstruments, Inc. @mmimicro_inc]

Major milestone for the REMIND Clinical Study: A multidisciplinary team at @BaptistHealthJx has completed the first study procedure, enrolling the first patient in this exploratory research evaluating robotic-enabled microsurgery in Alzheimer's disease. https://t.co/gCRzGyAm18